Shall we start off with a sweeping generalisation? This is a blog after all. Over the years it has been my impression that researchers care quite a lot about what happens next with their scientific discovery, whether it be identifying a genetic mutation or running a clinical trial. The problem is, research funders don't. They... Continue Reading →
I seem to be visiting more CLAHRCs (Collaboration for Leadership in Applied Health Research and Care) next week than in all my time as a boy looking for new school shoes. One of the CLAHRCs unfortunate enough to be visited by me is Northwest London. They've just launched a brilliant new tool to help patients... Continue Reading →
I am not sure what made me think about and look for this report: 'N=1: Why people matter in medicines.' Perhaps it was all the talk last week about the Department of Health's 11th report to parliament on the Pharmaceutical Price Regulation Scheme (PPRS) - in essence the way in which drug prices are set... Continue Reading →
This committee may be going quietly about its business but sometimes a 'nudge nudge, wink wink' can speak volumes.
I have just returned from the Financial Times' offices, where I was the guest for their regular science podcast hosted by Clive Cookson and Andrew Jack (it will appear here later today). The theme of the discussion was 'Selling Sickness.' Andrew was reporting on a recent conference of the same name that took place last month in Holland. ... Continue Reading →